GlassScriptPhysician profile
Sridevi Kodali
NPI 1053358630
$7,122.49
in general payments reported to CMS, 2019-2025
32 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $249 · 2021: $1,164 · 2022: $2,194 · 2023: $1,432 · 2024: $658 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $751.96 | 2019-2025 | Rexulti, Brintellix |
| Vanda Pharmaceuticals INC. | $705.49 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $684.35 | 2021-2024 | Aristada, Lybalvi |
| Validus Pharmaceuticals LLC | $527.01 | 2019-2025 | Raldesy, Equetro |
| Supernus Pharmaceuticals, INC. | $491.87 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $441.79 | 2019-2022 | |
| Abbvie INC. | $424.15 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $397.50 | 2019-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $373.35 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Ironshore Pharmaceuticals INC. | $365.76 | 2019-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $360.13 | 2019-2025 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $330.75 | 2022-2023 | Auvelity |
| Corium, LLC | $229.08 | 2022-2024 | Azstarys |
| Almatica Pharma LLC | $192.61 | 2021-2024 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.85 | 2021-2025 | Caplyta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $119.54 | 2019-2023 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $60.75 | 2019-2025 | |
| Neos Therapeutics, LP | $60.11 | 2019 | |
| Bausch Health US, LLC | $56.70 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $44.90 | 2022-2023 | Quviviq |
| Eisai INC. | $42.23 | 2021 | |
| Shire North American Group INC | $41.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.17 | 2024-2025 | Cobenfy |
| Indivior INC. | $36.62 | 2021 | |
| Vertical Pharmaceuticals, LLC | $29.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.70 | 2019 | |
| Janssen Biotech, INC. | $26.22 | 2025 | Carvykti |
| Adlon Therapeutics L.P. | $23.90 | 2019-2020 | |
| Livanova USA, INC. | $20.04 | 2021 | |
| Merck Sharp & Dohme LLC | $18.23 | 2022 | |
| Acadia Pharmaceuticals INC | $12.80 | 2019 | |
| Allergan, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sridevi Kodali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.